Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates
- 22 July 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 585 (7826), 584-587
- https://doi.org/10.1038/s41586-020-2558-4
Abstract
COVID-19 has rapidly become a pandemic for which no antiviral drug or vaccine is yet available2–4. Several clinical studies are ongoing to evaluate the efficacy of repurposed drugs that have demonstrated antiviral efficacy in vitro. Among these candidates, hydroxychloroquine (HCQ) has been given to thousands of individuals worldwide but definitive evidence for HCQ efficacy in treatment of COVID-19 is still missing6,7,17,18. We evaluated the antiviral activity of HCQ both in vitro and in SARS-CoV-2-infected macaques. HCQ showed antiviral activity in African green monkey kidney cells (VeroE6) but not in a model of reconstituted human airway epithelium. In macaques, we tested different treatment strategies in comparison to placebo, before and after peak viral load, alone or in combination with azithromycin (AZTH). Neither HCQ nor HCQ+AZTH showed a significant effect on the viral load levels in any of the tested compartments. When the drug was used as a pre-exposure prophylaxis (PrEP), HCQ did not confer protection against acquisition of infection. Our findings do not support the use of HCQ, either alone or in combination with AZTH, as an antiviral treatment for COVID-19 in humans.Keywords
This publication has 31 references indexed in Scilit:
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Characterization of cellular transcriptomic signatures induced by different respiratory viruses in human reconstituted airway epitheliaScientific Reports, 2019
- Macrolide derivatives reduce proinflammatory macrophage activation and macrophage‐mediated neurotoxicityCNS Neuroscience & Therapeutics, 2019
- Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkersInflammopharmacology, 2018
- Paradoxical Effect of Chloroquine Treatment in Enhancing Chikungunya Virus InfectionViruses, 2018
- Simultaneous quantitation of hydroxychloroquine and its metabolites in mouse blood and tissues using LC–ESI–MS/MS: An application for pharmacokinetic studiesJournal of Chromatography B, 2017
- Hydroxychloroquine in systemic lupus erythematosus (SLE)Expert Opinion on Drug Safety, 2016
- Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseasesInflammopharmacology, 2015
- New insights into the antiviral effects of chloroquineThe Lancet Infectious Diseases, 2006
- A dose‐ranging study of the pharmacokinetics of hydroxy‐chloroquine following intravenous administration to healthy volunteers.British Journal of Clinical Pharmacology, 1988